You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology III (MP46)1 May 2024MP46-04 REZUM FOR BPH: RESULTS FROM a LARGE RETROSPECTIVE MULTICENTER STUDY Clara Cerrato, Vi Nguyen, Mimi Vi Nguyen, Savio Domenico Pandolfo, Mikki Leach, Raffaele Balsamo, Francesco Uricchio, Juan A. Fulla, Dean Elterman, Kevin Zorn, Naeem Bhojani, Bilal Chughtai, and Seth K. Bechis Clara CerratoClara Cerrato , Vi NguyenVi Nguyen , Mimi Vi NguyenMimi Vi Nguyen , Savio Domenico PandolfoSavio Domenico Pandolfo , Mikki LeachMikki Leach , Raffaele BalsamoRaffaele Balsamo , Francesco UricchioFrancesco Uricchio , Juan A. FullaJuan A. Fulla , Dean EltermanDean Elterman , Kevin ZornKevin Zorn , Naeem BhojaniNaeem Bhojani , Bilal ChughtaiBilal Chughtai , and Seth K. BechisSeth K. Bechis View All Author Informationhttps://doi.org/10.1097/01.JU.0001008668.53858.38.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We sought to determine predictors of post-operative outcomes and adverse events for patients who underwent Rezum treatment for BPH. METHODS: We performed a multi-institutional retrospective review of patients who underwent Rezum procedure for symptomatic BPH between April 2019 and November 2022. Patients' demographics, pre- and peri-operative data, prostate volume (PV) and total international prostate symptoms score (IPSS) were evaluated.. Primary outcomes were predictors for development of post-operative adverse events (AEs) at one month follow up (persistent irritative symptoms [PIS], de novo UTI, retention or bleeding, or surgical retreatment by one year).Patients with pre-operative urinary retention requiring catheterization were excluded. RESULTS: 798 patients were included in the analysis, with 177 (22.2%) having AEs, the majority of which was retention (12.3%) (Table 1). 42(5.3%) patients had persistent irritative symptoms at one month postop (PIS), and 22 (2.8%) patients required retreatment within one year. AE group showed older age, larger prostate volumes, more treatments and longer post-operative catheterization(all significant). On multivariate analysis (MVA), decreasing pre-operative IPSS was associated with a higher overall probability of AEs (B -0.005,p=0.044) and PIS(B -0.003,p=0.020).Absence of median lobe(B -0.040, p=0.039) and decreasing PV/treatment ratio (more treatments per unit volume) (B -0.004,p=0.033) were independently associated with higher probability of de-novo UTI, whereas presence of median lobe (B 0.070,p=0.004), decreasing pre-op IPSS (B -0.004,p=0.035) and decreasing PV/treatment ratio (B -0.005,p=0.046) were associated with higher risk of development de-novo urinary retention. Higher preop IPSS scores were associated with higher postop IPSS scores at 1, 3-6 and 12 months (p<0.001). CONCLUSIONS: Our results confirm that Rezum is a safe and effective option for patients undergoing treatment for BPH with low AEs and retreatment rates. Pre-op IPSS, PV/treatment ratio, and presence of median lobe may help predict the development of postoperative AEs, but our study is limited by overall low numbers of AEs. Further analyses and longer follow-up are needed. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e753 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Clara Cerrato More articles by this author Vi Nguyen More articles by this author Mimi Vi Nguyen More articles by this author Savio Domenico Pandolfo More articles by this author Mikki Leach More articles by this author Raffaele Balsamo More articles by this author Francesco Uricchio More articles by this author Juan A. Fulla More articles by this author Dean Elterman More articles by this author Kevin Zorn More articles by this author Naeem Bhojani More articles by this author Bilal Chughtai More articles by this author Seth K. Bechis More articles by this author Expand All Advertisement PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Cerrato et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: